CJC-1295 Side Effects in the Research Literature

CJC-1295 side effects reported in published studies

CJC-1295 side effects reported in published studies

The phase-1 single-ascending-dose and multi-dose trials of CJC-1295 with DAC in healthy adults reported transient injection-site reactions, facial flushing, headache, and mild nausea among the more common acute effects, with no serious adverse events at the doses studied (30 to 250 µg/kg single dose; 60 µg/kg weekly or every other week multi-dose) ^[1][16]. The FDA's 2024 briefing document for the Pharmacy Compounding Advisory Committee separately reviewed the available CJC-1295 safety record and discussed peptide aggregation, immunogenicity, and adverse events including cardiovascular signals associated with the DAC variant ^[13]. Long-term human safety data does not exist in peer-reviewed literature; the longest published dosing window in healthy adults is the 49-day Teichman multi-dose arm ^[16].

Why CJC-1295 can cause flushing

Why CJC-1295 can cause flushing

Transient facial flushing was reported as one of the more common acute effects in the Teichman 2006 phase-1 trial of CJC-1295 with DAC ^[1]. The mechanism is consistent with the vasodilatory action that accompanies pulsatile growth-hormone release — GHRH-receptor agonism produces a brief vasoreactive response in addition to the somatotroph-stimulating effect ^[1]. Flushing in the reported phase-1 cohort was self-limiting and did not require intervention at the doses tested.

CJC-1295 and hair: what the literature does and does not show

CJC-1295 and hair: what the literature does and does not show

Hair loss is not reported as an effect in the published phase-1 trials of CJC-1295 with DAC ^[1][16]. Anecdotal user reports exist on consumer forums but are outside the peer-reviewed evidence base. This is an absence-of-reported-evidence statement rather than a safety clearance: the indexed phase-1 record did not measure or describe hair-related endpoints, so the literature establishes neither presence nor absence of the effect.

CJC-1295 and body composition: what trials measured

CJC-1295 and body composition: what trials measured

Published phase-1 trials of CJC-1295 with DAC in healthy adults measured biochemical endpoints (plasma GH, IGF-1, proteomic profile shifts) rather than scale weight ^[1][4][16]. The Alba 2006 murine GHRH-knockout study measured body weight, lean mass, and subcutaneous fat distribution — and reported normalization of all three to control levels after daily CJC-1295 administration in the knockout model ^[3]. Transient water retention has been described qualitatively in the GHRH-analog class. Long-term human body-composition data for CJC-1295 specifically is limited.

Fertility data and CJC-1295

Fertility data and CJC-1295

No published human fertility trials exist for CJC-1295. Animal reproductive-toxicology data for CJC-1295 specifically is not present in the publicly indexed peer-reviewed literature. The compound acts upstream on the GHRH/GH/IGF-1 axis rather than directly on the hypothalamic-pituitary-gonadal axis, so any reproductive effect would be expected to be indirect — but this is mechanistic reasoning, not data.

What the safety literature says about CJC-1295

What the safety literature says about CJC-1295

Published phase-1 human trials reported short-term tolerability at the doses tested, with no serious adverse events at single doses of up to 250 µg/kg or at 60 µg/kg weekly or every other week for 49 days ^[1][16]. The compound is not FDA-approved for any indication ^[13]. A phase-2 trial of CJC-1295 with DAC in HIV-associated lipodystrophy was halted after a fatal cardiovascular event approximately two hours after the eleventh weekly dose; the trial investigator attributed the event to pre-existing coronary atherosclerosis judged unrelated to study drug, and the sponsor concluded the event was unrelated to the compound, but the development program did not progress past phase 2 ^[14]. The FDA's 2023 placement of CJC-1295 in Category 2 of the interim 503A bulks list cited peptide-aggregation, immunogenicity, and adverse-event concerns ^[13]. The compound was removed from Category 2 in September 2024 on nominator withdrawal, which is an administrative outcome rather than a safety clearance ^[13]. Long-term human safety data does not exist in peer-reviewed literature.

Regulatory caveats

WADA classifies CJC-1295 under Section S2.2 of the Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a Growth Hormone Releasing Factor, prohibited at all times in and out of competition for athletes subject to the WADA Code ^[12]. The compound is widely sold as a 'research chemical' from suppliers outside FDA oversight; analytical studies of seized preparations have confirmed the published sequence and structure but do not provide quality assurance for any specific commercial product ^[5]. Sustained GH/IGF-1 elevation theoretically raises questions about long-term effects on insulin sensitivity, neoplasia risk, and acromegalic features — these questions are unresolved in the published evidence base for CJC-1295 specifically.